Kornimate/medical-research-clean huggingface dataset:
evaluation of the relationship between neck pain and ergonomic factors in office workers

Conditions: Disability Physical; Neck Pain; Ergonomic Factors

Summary: neck pain is a prevalent condition and leading causes of disability particularly in office workers compared to other occupations (1-3). neck pain is not only a risk factor for functional disability but it is also associated with decreased productivity of workers and quality of life (4). however, the present literature is insufficient to determine the factors affecting the level of disability caused by neck pain among office workers where intensive computer use is common (5). thus, the current study aimed to explore the associations between disability levels and of occupational risk factors in computer-using office workers with neck pain.

this is a cross-sectional study. all participants will provide informed consent before participating in the study. the study will be conducted in accordance with the helsinki declaration criteria. data will be collected using questionnaires, which include the neck disability index, demographic information (including age, gender, educational level) and frequency of neck and head pain, history of general neck injuries and treatments applied. also, years of office work at current job, sick leave, ergonomic training, duration of computer use per day and using of headphones, monitor and keyboard stand, mouse/mouse pad and number of computer screens will be determined. in addition, based on rapid office strain assessment (rosa) method the potential ergonomic risk factors computer position, computer screen position, head and back position and mouse position will be determined. visual pictures of the work positions will be shown to the participants and the participants will be asked to select the appropriate pictures showing their work positions. a self-administered questionnaire will be used to screen potential participants for this study. inclusion criteria are individuals aged between 18 and 55, working on computer, having neck pain at least three months. exclusion criteria are reporting pregnancy, having a history of accidents, trauma or surgery in the neck region, congenital anomaly of the spine, rheumatologic disease, osteoporosis, spondylosis, spondylolisthesis, infection of the spine and discs, tumor. patients will be divided into 3 groups as mild, moderate and severe disabled according to their neck disability index values and will be analyzed statistically.

Eligibility criteria:
inclusion criteria: * aged between 18 and 55, * working on computer, * having neck pain at least three months. exclusion criteria: * reporting pregnancy, * having a history of accidents, * trauma or surgery in the neck region, * congenital anomaly of the spine, * rheumatologic disease, * osteoporosis, * spondylosis, * spondylolisthesis, * infection of the spine * cervical disc herniation, * tumor.

Keywords: neck pain office workers ergonomic factors
study of 18f-dcfpyl, a second generation low-molecular weight psma-based pet radiotracer, in patients with prostate cancer

Conditions: Metastatic Prostate Cancer

Summary: this study is being done to determine the safety, biodistribution, and radiation dosimetry of 18f-dcfpyl, and to detect prostate cancer by visual analysis.

to assess the hypothesis that this new 2nd generation positron emission tomography (pet) radiopharmaceutical, 18f-dcfpyl, may possess pharmacokinetic and pharmacodynamic properties that will represent an advance in imaging metastatic prostate cancer in ten patients diagnosed with metastatic prostate cancer.

Eligibility criteria:
inclusion criteria: * patients may be enrolled into this protocol only if all of the following inclusion criteria are met: 1. greater than or equal to 18 years of age 2. histological confirmation of prostate cancer 3. radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (ct, mri, or ultrasound), bone scintigraphy, 18f-sodium fluoride pet, or 18f-fdg pet 4. psa ≥ 1.0 ng/ml 5. can be on androgen deprivation therapy if dose is stable for ≥ 1 week. 6. platelet count \> 50,000/mm3 7. neutrophil count \> 1,000/mm3 8. patient is judged by the investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits. 9. patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures. exclusion criteria: * patients will be excluded from enrollment if any of the following apply: 1. karnovsky performance status of \< 60 2. inadequate venous access (two antecubital or equivalent venous access sites are required for study drug injection and pk blood sampling, respectively) 3. patient received a permanent prostate brachytherapy implant within the last 3 months (for pd-103 implants) or 12 months (for i-125 implants) 4. administered a radioisotope within 5 physical half-lives prior to study enrollment 5. serum creatinine \> 3 times the upper limit of normal 6. total bilirubin \> 3 times the upper limit of normal 7. liver transaminases \> 5times the upper limit of normal 8. patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 30 days prior to study radiotracer administration 9. prior radiation therapy or chemotherapy within 2 weeks prior to study radiotracer administration (washout is one half-life of the drug or 2 weeks, whichever is longest). 10. prior history of any other malignancy within 3 years, other than skin basal cell carcinoma.

Keywords: metastatic prostate cancer
optic disc, macula, and retinal nerve fiber layer measurements obtained by oct in thyroid associated ophthalmopathy

Conditions: Thyroid Associated Ophthalmopathy

Summary: the aim of the study is to compare the measurements of retinal nerve fiber layer (rnfl), macula and optical disc parameters obtained by optical coherence tomography (oct), and intraocular pressure (iop) between the patients with thyroid-associated ophthalmopathy (tao) and healthy controls.

one hundred and thirty two eyes of 66 patients with tao and 72 eyes of 36 healthy controls were included in the study. proptosis level was determined by hertel exophthalmometer. optic disc, peripapillary retinal nerve fiber layer and macula parameters were measured by oct. all measurements were compared between the patients and age and sex-matched healthy controls.

Eligibility criteria:
inclusion criteria: patient group consists the consecutive patients with thyroid associated ophthalmopathy consulted by endocrinology department. the control group was chosen among healthy volunteers who have * no eye pathology, * 20/20 vision (corrected or uncorrected), * age and sex-matched with the patient group. exclusion criteria: for both groups, those who had * significant sight impairment, * high myopia ( \< -5diopters ), * high hyperopia ( \> +3diopters ), * optic disc anomaly, * vitreoretinal interface disease, * vascular and degenerative retinal diseases, * cornea or lens opacity, ocular surgery history, * glaucoma, * neurological diseases that can affect the visual field, * history of trauma, amblyopia, * diplopia, * keratitis, * history of topical or systemic steroid

Keywords: thyroid ophthalmopathy optical coherence tomography
efficacy and tolerability of intranasal fentanyl spray for the treatment of breakthrough pain in cancer patients older than 18 years

Conditions: Breakthrough Pain; Cancer

Summary: the aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (btp) attacks. the fentanyl spray was applied into the nose by a metered-spray device. the study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.


Eligibility criteria:
inclusion criteria: * decision to start treatment with intranasal fentanyl spray * written informed consent exclusion criteria: * criteria as defined in the summary of product characteristics (fachinformation chapter 4.3)

Keywords: intranasal fentanyl spray
computer assisted measurement of colorectal polyps

Conditions: Colonic Polyp

Summary: adenomas are polyps of the colorectum that have the potential to develop into colon cancer. however, some adenomas never become malignant tumors, or if so, progression from adenoma into cancer takes a long time. as a result, screening colonoscopy programs were established in order to detect and resect adenomas at an early stage. after resection, polyps should be sent to pathology in order to make a histological diagnosis. approximately 40-50% of all polyps have adenomatous histology whereas others contain benign histology (e.g. hyperplastic or inflammatory polyps). the latter polyps do not bear the risk to develop colon cancer. the bigger a polyp is the greater the chance is of it being malignant. during colonoscopy polyp size can be estimated visually by comparing the polyp with an opened biopsy forceps. the span of an opened forceps is 7 mm. prior to using this technique, the forceps has to be inserted into the colon through a small working channel of the endoscope. information on the actual adenoma size is crucial as surveillance recommendations depend on the size of the resected polyps. moreover current guidelines contain the possibilities to disregard hyperplastic polyps in the sigmoid colon if the polyp size is below 5 mm. this means that diminutive hyperplastic polyps (\< 5mm) do not necessarily require resection due to their benign dignity. however, there is increasing evidence that large human bias effects exist in estimating the size of polypoid lesions. for example, it has been shown that endoscopists exhibit terminal digit preferences leading to an exaggeration of estimated polyp size. in consequence the human bias problem might lead to wrong adenoma surveillance decisions. there is no doubt that technical devices are needed which can support endoscopists in finding the right declaration of polyp sizes. the aim of the current project is to create a computer program that is able to automatically measure polyp sizes during colonoscopy.


Eligibility criteria:
inclusion criteria: * indication for colonoscopy * patients \>= 18 years exclusion criteria: * pregnant women * indication for colonoscopy: inflammatory bowel disease * indication for colonoscopy: polyposis syndrome * indication for colonoscopy: emergency colonoscopy e.g. acute bleeding * contraindication for polyp resection e.g. patients on warfarin
prophylactic preoperative hipec in advanced gastric cancer at high risk of peritoneal recurrence

Conditions: Gastric Cancer

Summary: the study was designed to evaluate the efficacy of perioperative flot chemotherapy in combination with perioperative hyperthermic intraperitoneal chemotherapy (hipec) in patients with advanced gastric cancer at high risk of peritoneal metastases. the impact of treatment on peritoneal recurrence and survival over 6 months, 1, 3 and 5 years will be assessed.

this is a randomized, multicenter, clinical trial in which 598 patients with advanced gastric cancer at high risk of peritoneal metastases are randomly allocated to receive either preoperative hyperthermic intraperitoneal chemotherapy (hipec) plus gastrectomy (experimental group) or gastrectomy alone (control group). all patients, regardless of allocation, will additionally receive 4 cycles of flot chemotherapy (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 and 5-fluorouracil 2600 mg/m2) before surgery ± hipec and 4 cycles of flot chemotherapy after gastrectomy. the main outcome is frequency of peritoneal recurrence by 6-months post-operative. patients will be followed for 5 years and undergo additional evaluations at 6 months, 1 year, 3 and 5 years. the study will take place at 7 hospitals across poland. all participating centers have the equipment and skills to perform all necessary procedures in this study. the below centers specialize in the treatment of stomach cancer with many documented years of experience. they are trained in the maintenance of a register, possess the skills to conduct appropriate research analyses and are equipped with a system for assessing the quality of both surgical and oncological treatment.

Eligibility criteria:
inclusion criteria: * gastric cancer confirmed histopathologically in tumor specimens. * age 18-75 years. * advanced gastric cancer ct3 / ct4a / n0-3b. * no distant metastases on computed tomography (ct) scan of the chest, abdomen and pelvis (cm0). * written consent to participate in the study. exclusion criteria: * no clear histopathological confirmation of gastric cancer. * age \> 75 years. * poor general condition (performance status 3 or more on the eastern cooperative oncology group (ecog)/world health organization scale). * previous abdominal surgery (including oncological surgery), other than laparoscopic cholecystectomy or appendectomy (open or laparoscopic). * pregnancy and lactation. * refusal to participate or an inability to provide written consent. * coexisting cancer in another location. * systemic treatment or radiotherapy for another cancer. * dysphagia requiring surgical treatment (gastric resection or nutritional jejunostomy) before starting neoadjuvant treatment and indication for accelerated surgery for other reasons. * disqualification for perioperative flot4 chemotherapy as decided by a multi-specialist consultation.

Keywords: hipec flot gastric cancer lymphadenectomy
effect of enteral genistein supplementation in sepsis

Conditions: Sepsis

Summary: to evaluate effects of genistein supplementation to enteral nutrition on inflammatory cytokines and morbidity in patients with sepsis

sepsis is a state develops as a response to severe infection with high mortality rate. incidence of sepsis among patients admitted to hospitals is 2%. annual incidence of sepsis is 50-95 for 100.000 population and incidence is increasing approximately 9% each year. severe sepsis and septic shock is the most frequent reason for mortality in intensive care units (icu). there is exaggerated and irregular host response in sepsis. cytokines such as interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor-α, interferon-γ and high mobility group box-1 are released as response to invading microorganisms and they play a major role in sepsis pathogenesis. soybean proteins are used for prevention and treatment of cardiovascular diseases, osteoporosis and different cancer types. soy isoflavones such as genistein, daidzein and glycitein are the main components for cancer prevention. genistein is the dominant isoflavones. the main mechanism for anti-inflammatory effect of genistein is related to transcription nuclear factor (nf-kb) and inhibition of chemokine-8. the risk for prostate cancer was proven to decrease in epidemiological studies. nf-kb plays a central role for inflammatory cytokine release, prevents apoptosis and induces tumor cell growth. the effect of topoisomerase ii inhibitory chemotherapeutic agents is increased with nf-kb inhibition. hypothesis 1. addition of genistein to enteral nutrition in patients with sepsis can play an important role to decrease inflammatory cytokines. 2. morbidity can be decreased with lower levels of inflammatory cytokines in patients with sepsis.

Eligibility criteria:
criteria: inclusion criteria: * patients with sepsis above 18 years of age. * expected duration of icu survival more than 48 hours. * patients receiving enteral nutrition (en) * sepsis diagnosis within first 12 hours exclusion criteria: * presence of thyroid dysfunction * presence of hyperlipidemia * patients with nill by mouth and not receiving enteral nutrition

Keywords: enteral nutrition genistein cytokine
pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric malaria

Conditions: Malaria

Summary: the purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum malaria in kenyan children.


Eligibility criteria:
inclusion criteria: * children between 6 months and 12 years old, with a body weight of ≥5 kg; * living in the catchment area of the study (within a radius of \~10 km from st. jude's clinic, mbita, kenya); * having microscopically confirmed p. falciparum mono-infection (asexual parasite density 1,000-200,000 µl-1). exclusion criteria: * signs and symptoms of severe malaria (according to who criteria for severe malaria, (who 2012)) or any other severe illness necessitating parenteral treatment; * mixed plasmodium infection; * clinically suspected (oedema, jaundice and/or ascites) or reported hepatic and/or renal impairment (any cause, as reported by parents/guardians and/or evident from medical history); * having anaemia with an hb \<6 g/dl; * evidence of severe malnutrition (severe wasting: z-score weight for age \<-3 and severe stunting: z-score height for age \<-3 (who 2009b)); * having received anti-malarial therapy in the previous two weeks; * known history of hypersensitivity, allergic or adverse reactions to artesunate, artemether-lumefantrine or other artemisinins; * participating in other anti-malarial drug intervention studies; * previous participation in the paal study, e.g. in the previous transmission season (each individual child can only take part in this study once); * not being available for follow-up.
soluble cluster of differentiation 160 (scd160) in sera and intra-ocular fluids: association with ischaemic retinopathies

Conditions: Diabetic Retinopathy; Retinal Vein Occlusion

Summary: cd160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human cd160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the vegf/vegf-r pathway. a soluble form of cd160, scd160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an elisa test. the investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and scd160 concentrations in the vitreous, the aqueous humour and the serum.

120 patients enrolled for ophthalmic surgery (cataract or posterior segment surgery (epiretinal membrane, macular hole, vitrectomy)) will be recruited in the department of ophthalmology, robert debré hospital, reims, france. each patient will benefit a complete ophthalmologic examination, and either an aqueous sampling (cataract) or a vitreous sampling (posterior segment) along with a serum sampling at the beginning of the surgery. elisa test will be performed on vitreous or aqueous samples in triplicates. luminex will be performed on vitreous samples in order to determine the concentrations of several ischemia biomarkers (vegf, plgf, platelet-derived growth factor (pdgf-b), sdf-1, angpt2, interieukin il-6, il-8, cd105, monocyte chemoattractant protein 1 (mcp-1), il-10, interferon-inducible protein-10 ( ip-10), il-1b and cd106, rage). primary objective is: - evaluation of the association between ischaemic retinopathies (patients with or without) and scd160 concentrations of the vitreous or the aqueous humours. secondary objectives are: * evaluation of the association between diabetic retinopathies (patients with or without) and scd160 concentrations of the vitreous, the aqueous humours and the sera. * evaluation of the association between several vitreous biomarkers of ischaemia and scd160 concentrations of the vitreous and the sera. * evaluation of the association between scd160 concentrations in the vitreous and the sera. * evaluation of the association between scd160 concentration in the aqueous humours and the sera.

Eligibility criteria:
inclusion criteria : * over 18 years old * with social security affiliation * willing to participate this study non-inclusion criteria : * any prior (3 months) or concomitant treatment with anti-vegf therapy, corticosteroids, or immunosuppressive agents * any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation * any serious allergy to the fluorescein sodium for injection in angiography * any history of previous systemic anti-vegf treatment * any history of inflammatory or auto-immune disease * any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria : * patients with c-reactive protein crp \> 10mg/ml (serum sampling during surgery)
cerebral blood flow changes in people with obesity after glucose consumption

Conditions: Obesity

Summary: this study evaluates the hypothesis that a meal constituted of only glucose produces differences in the brain blood flow in people with obesity that are not observed in people without obesity. these changes, at least in part, could explain the mechanisms involved in maintenance or development of obesity.


Eligibility criteria:
inclusion criteria: * live in ribeirão preto, são paulo - brazil. * age between 18 and 40 years old. * female gender. * regular menses. * weight inferior than 120 kg and body mass index (bmi) between 30 and 40 kg/m2, for the group with obesity. * bmi between 18,5 and 24,9 kg/m2, for the group without obesity. exclusion criteria: * high blood pressure, diabetes, glucose intolerance or impaired fasting glycemia, metabolic syndrome, hypothyroidism and any kidney, liver, heart or neurologic disease. * psychiatric disorders, alcoholism, smoking or illicit drug abuse. * pregnancy or desire to be pregnant * use of medications, excluding contraceptives. * contraindication for magnetic resonance imaging. * be in treatment for obesity.

Keywords: obesity single photon emission computed tomography functional neuroimaging